K27.F KODIAK SCIENCES DL-0001
- Market cap
- EUR 6.27B
- P/E
- -
- P/B
- 112.77x
- ROE
- -405.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is K27.F undervalued?
Graham numberThe Graham number of KODIAK SCIENCES DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KODIAK SCIENCES DL-0001 fundamental analysis
No fundamental analysis for KODIAK SCIENCES DL-0001 yet.
KODIAK SCIENCES DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KODIAK SCIENCES DL-0001
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-relat…
Full company profileKODIAK SCIENCES DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KODIAK SCIENCES DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -267M | -341M | -277M | -187M | -234M | -253M |
| EBITDA | - | -323M | -235M | -150M | -204M | -228M |
| Net Income | -267M | -334M | -260M | -176M | -230M | -248M |
| EPS | -5.15 | -6.38 | -4.96 | -3.34 | -3.72 | -3.94 |
| Balance Sheet | ||||||
| Total Assets | 904M | 667M | 479M | 336M | 352M | 257M |
| Total Liabilities | 241M | 230M | 214M | 185M | 194M | 196M |
| Shareholders' Equity | 663M | 436M | 266M | 150M | 157M | 61.1M |
| Cash & Short-term Investments | 732M | 190M | 286M | 168M | 210M | 126M |
| Cash Flow | ||||||
| Operating Cash Flow | -182M | -206M | -154M | -117M | -136M | -172M |
| Capital Expenditure | 63.3M | 47.4M | 41.4M | 400K | 506K | 2.59M |
| Free Cash Flow | -246M | -254M | -196M | -118M | -137M | -175M |
| Ratios | ||||||
| ROE | -40.3% | -76.5% | -98.0% | -117.2% | -146.1% | -405.3% |
| ROA | -29.5% | -50.1% | -54.3% | -52.5% | -65.4% | -96.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
KODIAK SCIENCES DL-0001 dividends
KODIAK SCIENCES DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns KODIAK SCIENCES DL-0001
- Insiders 5.16%
- Institutions 94.84%
- Public & others 0.00%
- Shares outstanding 62.8M
- Free float 36.6M
KODIAK SCIENCES DL-0001 company profile
- Company name
- KODIAK SCIENCES DL-0001
- Ticker
- K27.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 141
- Fiscal year end
- December
- Address
- 1250 Page Mill Road, Palo Alto, CA, United States, 94304
- Phone
- 650 281 0850
- Website
- kodiak.com
About KODIAK SCIENCES DL-0001
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
KODIAK SCIENCES DL-0001 management
9- Dr. Victor Perlroth M.D.Co-Founder, Chairman, CEO & President · born 1974
- Mr. John A. Borgeson CPA, M.B.A.Executive VP, CFO & Secretary · born 1963
- Mr. Wayne To M.Phil.Chief Technology Officer
- Dr. Dolly S. Chang M.D., M.P.H., Ph.D.Chief Scientific Officer
- Dr. Hong Liang Ph.D.Senior Vice President of Development · born 1972
- Dr. Stephen Raillard Ph.D.Senior Vice President of Chemical Development & Manufacturing
- Ms. Almas Qudrat M.Sc.Chief Quality Officer
- Dr. J. Pablo Velazquez-Martin M.D.Chief Medical Officer
- Dr. Laurent Ducay Ph.D.Senior VP of Biologics Development & Manufacturing